Wang Pei, Whiteaker Jeffrey R, Paulovich Amanda G
Fred Hutchinson Cancer Research Center, 1100 Fairview Avenue N., Seattle, WA 98109, USA.
Cancer Biol Ther. 2009 Jun;8(12):1083-94. doi: 10.4161/cbt.8.12.8634. Epub 2009 Jun 6.
Although the field of mass spectrometry-based proteomics is still in its infancy, recent developments in targeted proteomic techniques have left the field poised to impact the clinical protein biomarker pipeline now more than at any other time in history. for proteomics to meet its potential for finding biomarkers, clinicians, statisticians, epidemiologists and chemists must work together in an interdisciplinary approach. These interdisciplinary efforts will have the greatest chance for success if participants from each discipline have a basic working knowledge of the other disciplines. To that end, the purpose of this review is to provide a nontechnical overview of the emerging/evolving roles that mass spectrometry (especially targeted modes of mass spectrometry) can play in the biomarker pipeline, in hope of making the technology more accessible to the broader community for biomarker discovery efforts. Additionally, the technologies discussed are broadly applicable to proteomic studies, and are not restricted to biomarker discovery.
尽管基于质谱的蛋白质组学领域仍处于起步阶段，但靶向蛋白质组学技术的最新进展使该领域比历史上任何时候都更有可能影响临床蛋白质生物标志物流程。为了使蛋白质组学发挥其寻找生物标志物的潜力，临床医生、统计学家、流行病学家和化学家必须采用跨学科方法共同努力。如果每个学科的参与者都具备其他学科的基本工作知识，那么这些跨学科努力取得成功的机会将最大。为此，本综述的目的是对质谱（尤其是靶向质谱模式）在生物标志物流程中可以发挥的新兴/不断演变的作用进行非技术性概述，希望能让更广泛的群体更容易接触到该技术，以用于生物标志物发现工作。此外，所讨论的技术广泛适用于蛋白质组学研究，并不局限于生物标志物发现。
